Insights

Measuring The Value Of A Drug

As one of the fastest-rising categories of healthcare costs, pharmaceuticals need to develop a metric that explains pricing

The pharmaceutical industry is still struggling to justify why some treatments cost six- or seven-figures. Oliver Wyman explores how this sticker shock may bring much needed relevance to the true value behind value-based care.

Authors

  • David Campbell, Partner, Health & Life Sciences, Oliver Wyman
  • Joseph Mocanu, Principal, Health & Life Sciences, Oliver Wyman

Measuring The Value Of A Drug


DOWNLOAD PDF